Online inquiry

IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11614MR)

This product GTTS-WQ11614MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&IL3RA gene. The antibody can be applied in Acute myeloid leukemia (AML), Myelodysplastic syndromes (MDS) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Mus musculus; Humanized
RefSeq NM_000733.4; NM_001267713.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 3563
UniProt ID P07766; P26951
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11614MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6746MR IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA DS 992
GTTS-WQ5154MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CAN34D3-65
GTTS-WQ13571MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA QAX-576
GTTS-WQ9747MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA JR-141
GTTS-WQ7000MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA F-627
GTTS-WQ6155MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CP-751871
GTTS-WQ3385MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AT-005
GTTS-WQ11354MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-551
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW